Joshua M. Eizen - Mar 15, 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Legal Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen
Stock symbol
ANTX
Transactions as of
Mar 15, 2024
Transactions value $
$0
Form type
4
Date filed
3/18/2024, 07:28 PM
Previous filing
Feb 17, 2023
Next filing
Jul 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +30K +1225.99% $0.00 32.4K Mar 15, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +60K $0.00 60K Mar 15, 2024 Common Stock 60K $3.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
F2 Reflects the adjusted total which includes the purchase of 1,207 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on March 31, 2023.
F3 Reflects the adjusted total which includes the purchase of 1,240 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on September 29, 2023.
F4 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.